v3.26.1
Segment Reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases. The Company’s Chief Operating Decision Maker (the CODM) is its Chief Executive Officer. The CODM evaluates financial information on a consolidated basis for the purposes of allocating resources and assessing performance. Substantially all of the Company's assets are located in the United States.
The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Total revenues$129,861 $81,504 $235,259 $147,350 
Less:
Cost of sales10,376 6,929 19,598 12,780 
Topical roflumilast program costs
1,983 2,827 5,290 4,273 
ARQ-234 program costs1,302 845 12,305 2,034 
Other program costs 102 1,193 197 2,375 
Research and development compensation and personnel-related expenses11,366 9,779 22,411 19,417 
Selling, general and administrative expenses82,008 69,033 155,962 132,917 
Other segment expenses(1)
6,295 5,509 12,156 12,694 
Total operating expenses113,432 96,115 227,919 186,490 
Operating income (loss)16,429 (14,611)7,340 (39,140)
Interest income2,279 2,076 4,554 4,613 
Interest expense(3,406)(3,029)(7,774)(6,011)
Other income (expense), net
(157)20 (177)213 
Provision for income taxes136 342 229 621 
Segment and consolidated net income (loss)$15,009 $(15,886)$3,714 $(40,946)
(1) Other segment expenses include professional services related to research and development, medical affairs, depreciation and amortization expenses.